이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

능동적 건선 관절염을 가진 성인 참가자의 치료를위한 표적 요법 연구

2026년 11월 5일 업데이트: AbbVie

2 단계 다기관, 무작위, 무작위, 플랫폼 플랫폼 연구는 능동적 건선 관절염을 가진 성인 대상의 치료를위한 표적 요법 연구

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.

The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.

연구 개요

연구 유형

중재적

등록 (추정된)

300

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • California
      • Huntington Beach, California, 미국, 92648-5994
        • 모병
        • Newport Huntington Medical Group /ID# 272764
        • 연락하다:
          • Site Coordinator
          • 전화번호: 714-923-7112
    • Florida
      • Avon Park, Florida, 미국, 33825
        • 모병
        • Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
        • 연락하다:
          • Site Coordinator
          • 전화번호: 863-314-8555
      • Clearwater, Florida, 미국, 33765
        • 모병
        • Clinical Research Of West Florida - Phase I Unit /ID# 273198
      • Orlando, Florida, 미국, 32819
        • 모병
        • HMD Research LLC /ID# 273086
      • Tamarac, Florida, 미국, 33321
        • 모병
        • West Broward Rheumatology Associates /ID# 272892
      • Tampa, Florida, 미국, 33606
        • 모병
        • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
        • 연락하다:
          • Site Coordinator
          • 전화번호: (813) 870-1292
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
      • Skokie, Illinois, 미국, 60076
        • 완전한
        • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
      • Willowbrook, Illinois, 미국, 60527
        • 모병
        • Willow Rheumatology and Wellness /ID# 277354
    • Maryland
      • Cumberland, Maryland, 미국, 21502
        • 완전한
        • Klein & Associates /ID# 272829
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • 모병
        • Dartmouth-Hitchcock Medical Center /ID# 272702
        • 연락하다:
          • Site Coordinator
          • 전화번호: 603-650-4717
    • Ohio
      • Middleburg Heights, Ohio, 미국, 44130
        • 모병
        • Paramount Medical Research and Consulting /ID# 272757
    • Pennsylvania
      • Duncansville, Pennsylvania, 미국, 16635
        • 모병
        • Altoona Center For Clinical Research /ID# 272593
        • 연락하다:
          • Site Coordinator
          • 전화번호: 814-296-6108
    • Tennessee
      • Memphis, Tennessee, 미국, 38119
        • 모병
        • Private Practice - Dr. Ramesh C. Gupta /ID# 272897
    • Texas
      • Austin, Texas, 미국, 78745
        • 모병
        • Tekton Research - West Gate /ID# 272765
      • Frisco, Texas, 미국, 75035
        • 모병
        • Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
      • Houston, Texas, 미국, 77089-6142
        • 모병
        • Accurate Clinical Research - Houston /ID# 272754
      • San Antonio, Texas, 미국, 78251
        • 모병
        • Tekton Research, LLC /ID# 272901
      • Tomball, Texas, 미국, 77375
        • 모병
        • DM Clinical Research - Tomball /ID# 272760
      • Uherské Hradiště, 체코, 686 01
        • 모병
        • Medical Plus Research /ID# 272363
      • Zlín, 체코, 760 01
        • 모병
        • PV Medical Services /ID# 272368
    • Brno-mesto
      • Brno, Brno-mesto, 체코, 638 00
        • 모병
        • Revmatologie /ID# 272367
    • Moravian-Silesian Region
      • Hlučín, Moravian-Silesian Region, 체코, 748 01
        • 모병
        • L.K.N. Arthrocentrum /ID# 272366
    • Quebec
      • Sherbrooke, Quebec, 캐나다, J1G 2E8
        • 모병
        • Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
      • Trois-Rivières, Quebec, 캐나다, G9A 3X2
        • 모병
        • Centre de Recherche Musculo-Squelettique /ID# 274397
    • Saskatchewan
      • Saskatoon, Saskatchewan, 캐나다, S7H 0P4
        • 모병
        • Dr. Latha Naik Medical Professional Corporation /ID# 272803
    • Kuyavian-Pomeranian Voivodeship
      • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 폴란드, 85-068
        • 모병
        • Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
    • Masovian Voivodeship
      • Pruszków, Masovian Voivodeship, 폴란드, 05-800
        • 모병
        • MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
      • Warsaw, Masovian Voivodeship, 폴란드, 02-665
        • 모병
        • Centrum Medyczne Reuma Park /ID# 273301
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, 폴란드, 15-351
        • 완전한
        • Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
    • Warmian-Masurian Voivodeship
      • Elblag, Warmian-Masurian Voivodeship, 폴란드, 82-300
        • 완전한
        • Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
    • Alpes-Maritimes
      • Nice, Alpes-Maritimes, 프랑스, 06001
        • 모병
        • Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
    • Auvergne-Rhône-Alpes
      • Caluire-et-Cuire, Auvergne-Rhône-Alpes, 프랑스, 69300
        • 모병
        • Infirmerie Protestante De Lyon /ID# 273731
    • Indre-et-Loire
      • Chambray-lès-Tours, Indre-et-Loire, 프랑스, 37170
        • 모병
        • Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
    • Loiret
      • Orléans, Loiret, 프랑스, 45067
        • 완전한
        • Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
    • New Aquitaine
      • Bordeaux, New Aquitaine, 프랑스, 33076
        • 완전한
        • Chu Bordeaux - Hopital Pellegrin /ID# 273390
      • Budapest, 헝가리, 1027
        • 모병
        • Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
      • Budapest, 헝가리, 1023
        • 모병
        • Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
    • Borsod-Abauj Zemplen county
      • Miskolc, Borsod-Abauj Zemplen county, 헝가리, 3529
        • 모병
        • Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
    • Fejér
      • Székesfehérvár, Fejér, 헝가리, 8000
        • 모병
        • Complex Rendelo Med Zrt. /ID# 272570
      • Veszprém, Fejér, 헝가리, 8200
        • 모병
        • Vital-Medicina /ID# 272855

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
  • Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
  • Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
  • Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
  • Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA

Exclusion Criteria:

  • Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
  • Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
  • Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
  • History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Substudy 1: Risankizumab Monotherapy

Participants will receive risankizumab

Subcutaneous (SC) Injection

실험적: Substudy 1: Lutikizumab Monotherapy

Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week.

Subcutaneous (SC) Injection

실험적: Substudy 1: Lutikizumab and Risankizumab Combination Therapy

Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

Subcutaneous (SC) Injection

Subcutaneous (SC) Injection

실험적: Substudy 2: ABBV-701 Monotherapy

Participants will initially receive ABBV-701.

Subcutaneous (SC) Injection

실험적: Substudy 2: Risankizumab Monotherapy

Participants will receive risankizumab.

Subcutaneous (SC) Injection

실험적: Substudy 2: ABBV-701 and Risankizumab Combination Therapy

Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

Subcutaneous (SC) Injection

Subcutaneous (SC) Injection

실험적: Substudy 3: ABBV-547 Dose A

Participants will receive ABBV-547 Dose A.

Subcutaneous (SC) Injection

실험적: Substudy 3: ABBV-547 Dose B

Participants will receive ABBV-547 Dose B.

Subcutaneous (SC) Injection

실험적: Substudy 3: ABBV-547 Dose C

Participants will receive ABBV-547 Dose C.

Subcutaneous (SC) Injection

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
기간: At Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:

  1. ≥ 50% improvement in 68-tender joint count;

  2. ≥ 50% improvement in 66-swollen joint count; and

  3. ≥ 50% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Number of Participants With Adverse Events (AEs)
기간: Up to Week 52

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Up to Week 52

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response
기간: At Week 16

A participant was classified as achieving MDA if 5 of the following 7 criteria were met:

  • Tender joint count (out of 68 joints) ≤ 1
  • Swollen joint count (out of 66 joints) ≤ 1
  • PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3%
  • Participant's assessment of pain ≤ 1.5 (NRS from 0 to 10)
  • Participant's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10)
  • HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3)
  • Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)
At Week 16
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
기간: At Week 16

Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:

  1. ≥ 20% improvement in 68-tender joint count;

  2. ≥ 20% improvement in 66-swollen joint count; and

  3. ≥ 20% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
기간: At Week 16

Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria:

  1. ≥ 70% improvement in 68-tender joint count;

  2. ≥ 70% improvement in 66-swollen joint count; and

  3. ≥ 70% improvement in at least 3 of the 5 following parameters:

    • Physician global assessment of disease activity
    • Patient global assessment of disease activity
    • Patient assessment of pain
    • Health Assessment Questionnaire - Disability Index (HAQ-DI)
    • High-sensitivity C-reactive protein (hsCRP).
At Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)
기간: At Week 16

PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked).

The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.

At Week 16

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: ABBVIE INC., AbbVie

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 11일

기본 완료 (추정된)

2029년 8월 1일

연구 완료 (추정된)

2029년 8월 1일

연구 등록 날짜

최초 제출

2025년 3월 4일

QC 기준을 충족하는 최초 제출

2025년 3월 4일

처음 게시됨 (실제)

2025년 3월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • M25-191
  • 2024-519291-11 (Substudy 1) (기타 식별자: EU CT)
  • 2026-525937-21 (Substudy 2) (기타 식별자: EU CT)
  • 2026-527719-41 (Substudy 3) (기타 식별자: EU CT)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD 공유 기간

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

IPD 공유 액세스 기준

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다